Innovative retatrutide, a dual -action medication targeting simultaneously GLP-1 and GIP receptors, is sparking considerable buzz within the healthcare community. Initial clinical studies have revealed impressive reductions in body weight and gains in physiological markers for individuals with overweight. Experts believe this unique approach could